静脉注射免疫球蛋白：市售静脉注射免疫球蛋白制剂的演变
Intravenous immunoglobulins: evolution of commercial IVIG preparations.
作者信息
Hooper John A
机构信息
BioCatalyst Research LLC, 217 Camelot Drive, Liberty, MO 64068, USA.
出版信息
Immunol Allergy Clin North Am. 2008 Nov;28(4):765-78, viii. doi: 10.1016/j.iac.2008.06.002.
Abstract
Since its first use in 1952, human immunoglobulin has been used to treat people who have inherited antibody deficiencies. This article summarizes IVIG clinical development in primary immunodeficient patients and manufacturing improvements introduced over time. Manufacturing improvements include purification procedures that have reduced the incidence of adverse events and improved clinical efficacy, as well as virus inactivation and removal steps that have increased safety from blood-borne infections. Current manufacturing procedures, IVIG production trends, and recent clinical trial results are also reviewed.
摘要
自1952年首次使用以来，人免疫球蛋白一直用于治疗遗传性抗体缺陷患者。本文总结了静脉注射免疫球蛋白（IVIG）在原发性免疫缺陷患者中的临床发展情况以及随着时间推移所引入的生产改进。生产改进包括降低不良事件发生率并提高临床疗效的纯化程序，以及提高血源感染安全性的病毒灭活和去除步骤。还回顾了当前的生产程序、IVIG生产趋势和近期临床试验结果。
相似文献
1
Intravenous immunoglobulins: evolution of commercial IVIG preparations.静脉注射免疫球蛋白：市售静脉注射免疫球蛋白制剂的演变
Immunol Allergy Clin North Am. 2008 Nov;28(4):765-78, viii. doi: 10.1016/j.iac.2008.06.002.
2
Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies.一种纳米过滤静脉注射免疫球蛋白的疗效、耐受性、安全性及药代动力学：针对免疫性血小板减少性紫癜和原发性免疫缺陷患者的研究
Vox Sang. 2003 Jan;84(1):45-53. doi: 10.1046/j.1423-0410.2003.00255.x.
3
Efficacy and safety of a nanofiltered liquid intravenous immunoglobulin product in patients with primary immunodeficiency and idiopathic thrombocytopenic purpura.纳米过滤液体静脉注射免疫球蛋白产品在原发性免疫缺陷和特发性血小板减少性紫癜患者中的疗效和安全性。
Vox Sang. 2011 Aug;101(2):138-46. doi: 10.1111/j.1423-0410.2011.01476.x. Epub 2011 Mar 29.
4
Clinical experience with the viral safety of immunoglobulins.免疫球蛋白病毒安全性的临床经验。
Blood Coagul Fibrinolysis. 1994 Dec;5 Suppl 3:S31-4; discussion S35. doi: 10.1097/00001721-199412003-00008.
5
Intravenous immunoglobulin: more questions than answers.
Transfus Med Rev. 1991 Jul;5(3):165-70. doi: 10.1016/s0887-7963(91)70205-8.
6
Intravenous immunoglobulin (IVIg) for refractory and difficult-to-treat infections.静脉注射免疫球蛋白（IVIg）治疗难治性和治疗困难的感染。
Am J Med. 2012 Oct;125(10):1036.e1-8. doi: 10.1016/j.amjmed.2012.01.023. Epub 2012 May 16.
7
Pharmacovigilance study of a regional intravenous immunoglobulin (II): evaluation and comparison of an improved pharmaceutical form.一种局部静脉注射免疫球蛋白的药物警戒研究（II）：一种改良剂型的评估与比较
Allergol Immunopathol (Madr). 2006 Nov-Dec;34(6):242-7. doi: 10.1157/13095871.
8
Post-marketing observational study on 5% intravenous immunoglobulin therapy in patients with secondary immunodeficiency and recurrent serious bacterial infections.5%静脉注射用免疫球蛋白治疗继发免疫缺陷和复发性严重细菌感染患者的上市后观察性研究。
Microbiol Immunol. 2013 Jul;57(7):527-35. doi: 10.1111/1348-0421.12060.
9
Clinical experience with Flebogamma 5% DIF: a new generation of intravenous immunoglobulins in patients with primary immunodeficiency disease.5%二糖唾液酸纤维连接蛋白（Flebogamma DIF）的临床经验：原发性免疫缺陷病患者使用的新一代静脉注射免疫球蛋白
Clin Exp Immunol. 2009 Sep;157 Suppl 1(Suppl 1):22-5. doi: 10.1111/j.1365-2249.2009.03951.x.
10
Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants.静脉注射免疫球蛋白预防早产和/或低出生体重婴儿感染
Cochrane Database Syst Rev. 2004(1):CD000361. doi: 10.1002/14651858.CD000361.pub2.
引用本文的文献
1
Understanding supply sustainability of plasma-derived medicinal products: Drivers and consequences of shortages.了解血浆衍生药品的供应可持续性：短缺的驱动因素及后果
Vox Sang. 2025 Aug;120(8):754-764. doi: 10.1111/vox.70052. Epub 2025 May 26.
2
Immunoglobulin therapies for primary immunodeficiency diseases (part 1): understanding the pharmacokinetics.原发性免疫缺陷病的免疫球蛋白治疗（第 1 部分）：了解药代动力学。
Immunotherapy. 2024;16(13):879-894. doi: 10.1080/1750743X.2024.2382081. Epub 2024 Sep 26.
3
Comparative Analysis of Laboratory-Scale Immunoglobulin G Purification Methods from Human Serum.从人血清中进行实验室规模的免疫球蛋白 G 纯化方法的比较分析。
J Proteome Res. 2024 Sep 6;23(9):3933-3943. doi: 10.1021/acs.jproteome.4c00268. Epub 2024 Aug 14.
4
enhancement of Zika virus infection by preexisting West Nile virus antibodies in human plasma-derived immunoglobulins revealed after P2 binding site-specific enrichment.在 P2 结合位点特异性富集后，发现人血浆源性免疫球蛋白中预先存在的西尼罗河病毒抗体增强了寨卡病毒感染。
Microbiol Spectr. 2024 Jun 4;12(6):e0075824. doi: 10.1128/spectrum.00758-24. Epub 2024 Apr 30.
5
The use of intravenous immunoglobulin in intensive care.静脉注射免疫球蛋白在重症监护中的应用。
BJA Educ. 2024 Jan;24(1):31-37. doi: 10.1016/j.bjae.2023.10.004. Epub 2023 Nov 27.
6
Intravenous immunoglobulin therapy in immunoglobulin A vasculitis with gastrointestinal tract involvement.静脉注射免疫球蛋白治疗免疫球蛋白 A 血管炎伴胃肠道受累。
Clin Exp Med. 2023 Sep;23(5):1773-1782. doi: 10.1007/s10238-022-00950-w. Epub 2022 Nov 28.
7
Process steps for the fractionation of immunoglobulin (Ig) G depleted of IgA, isoagglutinins, and devoid of in vitro thrombogenicity.免疫球蛋白（Ig）G 去除 IgA、同种凝集素且无体外血栓形成活性的分级分离的步骤。
Blood Transfus. 2021 Nov;19(6):467-478. doi: 10.2450/2021.0159-21. Epub 2021 Aug 4.
8
Global immunoglobulin supply: steaming towards the iceberg?全球免疫球蛋白供应：驶向冰山？
Curr Opin Allergy Clin Immunol. 2020 Dec;20(6):557-564. doi: 10.1097/ACI.0000000000000696.
9
Role of intravenous immunoglobulin therapy in the survival rate of pediatric patients with acute myocarditis: A systematic review and meta-analysis.静脉注射免疫球蛋白治疗对小儿急性心肌炎患者生存率的影响：系统评价和荟萃分析。
Sci Rep. 2019 Jul 18;9(1):10459. doi: 10.1038/s41598-019-46888-0.
10
Efficacy and safety of a new intravenous immunoglobulin (Panzyga ) in chronic immune thrombocytopenia.一种新型静脉注射免疫球蛋白（Panzyga）治疗慢性免疫性血小板减少症的疗效与安全性。
Transfus Med. 2019 Feb;29(1):48-54. doi: 10.1111/tme.12573. Epub 2019 Jan 27.
本文引用的文献
1
Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids.血清和血浆蛋白的制备与性质；一种将生物组织和体液中的蛋白质和脂蛋白成分分离成各组分的系统。
J Am Chem Soc. 1946 Mar;68:459-75. doi: 10.1021/ja01207a034.
2
The separation of the antibodies, isoagglutinins, prothrombin, plasminogen and beta1-lipoprotein into subfractions of human plasma.将抗体、同种凝集素、凝血酶原、纤溶酶原和β1-脂蛋白分离成人血浆的亚组分。
J Am Chem Soc. 1949 Feb;71(2):541-50. doi: 10.1021/ja01170a048.
3
CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XXXVI. INACTIVATION OF THE VIRUS OF HOMOLOGOUS SERUM HEPATITIS IN SOLUTIONS OF NORMAL HUMAN SERUM ALBUMIN BY MEANS OF HEAT.人血浆成分制品的化学、临床及免疫学研究。三十六。通过加热法灭活正常人血清白蛋白溶液中同种血清性肝炎病毒
J Clin Invest. 1948 Mar;27(2):239-44. doi: 10.1172/JCI101939.
4
Partitioning of TSE infectivity during ethanol fractionation of human plasma.人血浆乙醇分级分离过程中传染性海绵状脑病感染性的分配
Biologicals. 2004 Mar;32(1):1-10. doi: 10.1016/j.biologicals.2003.08.004.
5
Agammaglobulinemia.无丙种球蛋白血症
Pediatrics. 1952 Jun;9(6):722-8.
6
[On new possibilities of intravenous gamma globulin administration].[关于静脉注射γ-球蛋白给药的新可能性]
Dtsch Med Wochenschr. 1962 Aug 24;87:1643-4 passim. doi: 10.1055/s-0028-1113997.
7
Intravenous administration of human gamma-globulin.静脉注射人γ球蛋白。
Vox Sang. 1962;7:157-74. doi: 10.1111/j.1423-0410.1962.tb03240.x.
8
Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process.一种新型静脉注射免疫球蛋白生产工艺中病毒和朊病毒去除效果的评估
Vox Sang. 2003 Apr;84(3):176-87. doi: 10.1046/j.1423-0410.2003.00279.x.
9
Removal of neutralized model parvoviruses and enteroviruses in human IgG solutions by nanofiltration.通过纳滤去除人免疫球蛋白溶液中的中和型细小病毒模型和肠道病毒
Transfusion. 2002 Aug;42(8):1005-10. doi: 10.1046/j.1537-2995.2002.00145.x.
10
Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.辛酸对包膜病毒的灭活作用：血浆衍生中间体中溶剂-去污剂处理的有效替代方法
Biologicals. 2002 Jun;30(2):153-62. doi: 10.1006/biol.2002.0334.
Zotero 插件